RxDoctor Payments Data

Benjamin Millar, MD

Neurology · San Antonio, TXNPI 1275526188

Payments from drug & device makers

$8,567in general payments, 2019–2025

Across 29 payments — averaging $295.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$8K
  • AbbVie$125
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • Ceribell, Inc.$117
  • Argenx US, Inc.$81
  • Novartis$48
  • plus $134 from 7 others

What the payments were for

  • Consulting fees$1,41016%
  • Speaking & faculty fees$6,34574%
  • Food & beverage$7769%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,567 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$144,650
Medicare patients
696
Services billed
5,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dimethyl Fumarate20$74,997
BriviactBrivaracetam41$70,694
FingolimodFingolimod Hcl13$63,664
Aimovig AutoinjectorErenumab-Aooe68$58,312
UbrelvyUbrogepant34$36,682
EpidiolexCannabidiol (Cbd)14$28,775
Ajovy AutoinjectorFremanezumab-Vfrm34$24,576
QuliptaAtogepant16$22,551
RexultiBrexpiprazole13$22,387
Nurtec OdtRimegepant Sulfate13$22,069
Glatiramer Acetate14$18,959
BotoxOnabotulinumtoxina13$17,485
Emgality PenGalcanezumab-Gnlm15$16,018
Lacosamide134$14,800
Levetiracetam438$12,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$125$76,71763 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →